SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: HardToFind who wrote (12113)4/16/2019 8:36:00 PM
From: old 'n cranky1 Recommendation

Recommended By
HardToFind

  Respond to of 12871
 
The Pre-IND meeting is optional, but from a risk perspective, highly recommended.
The FDA has indicated that rather than a meeting they will provide a written response.

"This written response will guide the Company's IND submission for this drug candidate and indication.
(Tuesday, April 9, 2019 press release)

Based on the Guidelines the Company already knows when they can expect that written response. They could have provided that date in today's PR but chose not to.

fda.gov
Line 303



To: HardToFind who wrote (12113)4/17/2019 9:47:32 AM
From: Another_Just_me  Read Replies (1) | Respond to of 12871
 
HTF this cide isn't a cancer fighter, it is a cream. Any chance you could revise to time schedule to account for this fact?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News